Literature DB >> 1563772

Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection.

R H Gelber1, L Murray, P Siu, M Tsang.   

Abstract

Groups of BALB/c mice were vaccinated intradermally with either Freund's incomplete adjuvant (FIA) alone, 10(7) heat-killed Mycobacterium leprae organisms in FIA, or a number of fractions of M. leprae containing soluble and/or cell wall components. At 1, 3, 6, 9, and 12 months later, vaccinated mice were challenged in the right hind footpad with 5,000 live M. leprae organisms, and vaccine protection was assessed 6 to 8 months later, at the peak of M. leprae multiplication in the negative control (FIA alone), by the two-sample rank-sum test. In these studies, a cell wall fraction rich in peptidoglycan was consistently ineffective. Both heat-killed M. leprae and a fraction containing cell wall and fixed proteins generally protected when the interval between vaccination and challenge was 1 or 3 months but not subsequently. On the other hand, soluble proteins of M. leprae alone or in combination (with cell wall fractions) consistently (14 of 14 instances) afforded highly significant protection (P less than or equal to 0.01) at all challenge intervals up to 1 year after vaccination. These results suggest that the soluble protein fraction of M. leprae offers promise for a vaccine against leprosy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1563772      PMCID: PMC257082          DOI: 10.1128/iai.60.5.1840-1844.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  BCG vaccination against tuberculosis in Chicago. A twenty-year study statistically analyzed.

Authors:  S R ROSENTHAL; M L GRAHAM; D LIVERIGHT; G THORNE; V JOHNSON
Journal:  Pediatrics       Date:  1961-10       Impact factor: 7.124

Review 2.  Signaling through phosphatidylcholine breakdown.

Authors:  J H Exton
Journal:  J Biol Chem       Date:  1990-01-05       Impact factor: 5.157

3.  Long-term results of BCG vaccination in the southern United States.

Authors:  G W Comstock; C E Palmer
Journal:  Am Rev Respir Dis       Date:  1966-02

4.  Identification, sequencing, and expression of Mycobacterium leprae superoxide dismutase, a major antigen.

Authors:  H S Thangaraj; F I Lamb; E O Davis; P J Jenner; L H Jeyakumar; M J Colston
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

5.  Mycobacterium leprae antigen-induced suppression of T cell proliferation in vitro.

Authors:  G Kaplan; R R Gandhi; D E Weinstein; W R Levis; M E Patarroyo; P J Brennan; Z A Cohn
Journal:  J Immunol       Date:  1987-05-01       Impact factor: 5.422

6.  Heterologous expression of the 65-kilodalton antigen of Mycobacterium leprae and murine T-cell responses to the gene product.

Authors:  F I Lamb; A E Kingston; I Estrada; M J Colston
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

7.  BCG vaccination of children against leprosy in Uganda: final results.

Authors:  S J Stanley; C Howland; M M Stone; I Sutherland
Journal:  J Hyg (Lond)       Date:  1981-10

8.  Isolation and characterization of the highly immunogenic cell wall-associated protein of Mycobacterium leprae.

Authors:  S W Hunter; M McNeil; R L Modlin; V Mehra; B R Bloom; P J Brennan
Journal:  J Immunol       Date:  1989-04-15       Impact factor: 5.422

9.  Selective primary health care: strategies for control of disease in the developing world. V. Leprosy.

Authors:  B R Bloom; T Godal
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

10.  A major T cell antigen of Mycobacterium leprae is a 10-kD heat-shock cognate protein.

Authors:  V Mehra; B R Bloom; A C Bajardi; C L Grisso; P A Sieling; D Alland; J Convit; X D Fan; S W Hunter; P J Brennan
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more
  5 in total

1.  Induction of Th1 cytokine responses by mycobacterial antigens in leprosy.

Authors:  H M Dockrell; S K Young; K Britton; P J Brennan; B Rivoire; M F Waters; S B Lucas; F Shahid; M Dojki; T J Chiang; Q Ehsan; K P McAdam; R Hussain
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

Review 2.  Hansen's disease.

Authors:  R H Gelber
Journal:  West J Med       Date:  1993-06

Review 3.  Chemotherapy of lepromatous leprosy: recent developments and prospects for the future.

Authors:  R H Gelber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

4.  Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection.

Authors:  Vanitha S Raman; Joanne O'Donnell; H Remy Bailor; Wakako Goto; Ramanuj Lahiri; Thomas P Gillis; Steven G Reed; Malcolm S Duthie
Journal:  Infect Immun       Date:  2009-09-28       Impact factor: 3.441

5.  Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads.

Authors:  R H Gelber; V Mehra; B Bloom; L P Murray; P Siu; M Tsang; P J Brennan
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.